Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/PepGen Inc./ EFFECT

Notice of Effectiveness · EFFECT

PepGen Inc.

PEPGNASDAQEQUITYCurrent

Notice of Effectiveness

Filed May 21, 2026Accepted May 22, 2026, 12:15 AM EDTCIK 1835597Accession 9999999995-26-001734
View company →Permanent SEC source ↗
Share

Company context

PepGen Inc. is a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases. Founded on more than a decade of research and development, PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using this EDO technology, PepGen is advancing PGN-EDODM1, a clinical candidate for the treatment of myotonic dystrophy type 1.

Current securities

PEPGNASDAQ · EQUITY · Current

Recent company filings

  1. Results of Operations and Financial Condition · Regulation FD Disclosure · Other EventsNov 10, 2026
  2. 10-Q filingNov 10, 2026
  3. Results of Operations and Financial Condition · Regulation FD Disclosure · Other EventsAug 6, 2026
  4. 10-Q filingAug 6, 2026
  5. Submission of Matters to a Vote of Security HoldersJun 22, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.